Loading provider…
Loading provider…
Emergency Medicine Physician in La Mesa, CA
NPI: 1104814680Primary Practice Location
GROSSMONT HOSPITAL
5555 Grossmont Center Dr, La Mesa, CA
Primary Employer
Team Physicians of Northern California Medical Group Inc
teamhealth.com
HQ Phone
Get MD Jeffrey's Phone Numberphone_androidMobile
Get MD Jeffrey's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
CA State Medical License
NC State Medical License
CA State Medical License
2008 - 2025
NC State Medical License
2001 - 2025
FL State Medical License
2004 - 2012
HI State Medical License
2003 - 2003

American Board of Emergency Medicine
Emergency Medicine
University of North Carolina Hospitals
Residency • Emergency Medicine
2001 - 2004
University of North Carolina School of Medicine
med.unc.edu
Medical School
Until 2001
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 93010Routine electrocardiogram (EKG) using at least 12 leads with interpretation and report | 15 | 15 |
| 2 | 99285Emergency department visit, problem with significant threat to life or function | 14 | 14 |
Single-dose oritavancin in the treatment of acute bacterial skin infections.
Authors: Christopher Lucasti, Purvi Mehra, William O'Riordan, Sandeep Gupta
Publication Date: 2014-06-05
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis
Authors: Franco Felizarta, Paul Kwo, Humberto Aguilar
Publication Date: 2017-08
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
Authors: William O'Riordan, Paul Eckburg
Publication Date: 2019-02-07
Lead Sponsor: Novavax
Collaborators: Department of Health and Human Services
Intervention / Treatment: BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination), OTHER: Placebo (Crossover Vaccination period), BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), OTHER: Placebo (Initial Vaccination Period), BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), BIOLOGICAL: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
Lead Sponsor: Daiichi Sankyo
Intervention / Treatment: DRUG: Placebo Capsule, DRUG: Placebo Tablet, DRUG: Sitagliptin 100 mg, DRUG: DS-8500a 25mg
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Donanemab